EVLO - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Evelo’s Conference Call for initial data results for clinical trials EDP1815 and EDP1066. [Operator Instructions] At this time, I would like to turn the call over to Stefan Riley of Evelo. Please proceed.

Stefan Riley

Thank you, operator. This morning, we issued a press release that outlines the topics that we plan to discuss today. at the available tab. is release www.evelobio.com Investors under This from CEO, Simba Duncan will Today future and clinical data strategy call, the Evelo’s significance review and together on their positive plans. Officer, in our and Medical Gill, with company’s EDPXXXX Chief McHale, the EDPXXXX our

to to data to cause updates speak draw to Evelo’s events Form in quarter statements attention the as other operations Private milestones that and including do and quarterly differ XXXX Before to and clinical and filings the not of views XXXX. I our Litigation for forward-looking we everyone provide Evelo for matters begin, anticipated could be forward-looking the forward-looking statements and this timing by potential Risk studies during of the harbor of Reform if Securities directed to of to statements set timing and any the made presentation. company’s like only Such would should be made Participants the by to provided I are those fact, ended like about clinical safe impact Commission. Factors and reform March the forward results indicated change. relate considered XX, Any the objectives forward-looking our results materially conference many clinical on forward-looking plans to the remind historical act. duty the the today accompanying any XXXX, to statements subject Securities of from call any to protection company’s within report to statements Exchange clinical studies factors. Actual the XX-Q and the data, due Act for that of are today. of statements your of Evelo’s statements microbials intended EDPXXXX of the disclaims monoclonal would meaning XXXX, subsequent its with even the

my now to over Simba. call is It to pleasure the pass

Simba Gill

important Good in started in for and with medicine play time bold you, small an the for which thank We the day. central biology morning, in is newly a governing transform understand role Today cells biology. our we Thank Evelo first you the uncovered harnessing to that Stefan. intestine everyone by joining us. vision

Our this class objective a biology. is to new all of based develop biologics on central

multiple in As I’m you work biology and evidence clinical across clinical that know, first translation, biomarkers. delighted and and simply, the for patients it phasing have preclinical in question quite well disease, models our terms in been humans? asking today to are data both we is as of you of will report as responses

the Slide into data. am X I we go highlights into to now Phase are Duncan, the details in clinical data. over who key of Notably, these will II going from psoriasis. hand EDPXXXX to advancing summarizes

Duncan McHale

Thank you, Simba.

So to trials. able the from share EDPXXXX you I’m and Ib be interim with data Phase pleased to clinical today EDPXXXX our

as well of the Moving to segment, ability X, to learn candidates. the patient in selected as as just diseases of as our the the first inflammatory need, psoriasis the mild-to-moderate about particularly unmet reminder, we clinical study pharmacology a one given Slide patient to

have potentially the Evelo’s any to of disease oral opportunity address profile biologics. of We the stage differentiated due to

stages of Our be across a goal first-line is treatment to all disease.

and Our across these therapies. patients This initial U.S. are on X.X focus the is current million by populations. over mild-to-moderate numbers underserved population the patients EUX, and

response was safety to This ratio patients daily well of this Moving from tolerability. The no in psoriasis. short-duration also the pharmacodynamic low-dose for primary EDPXXXX of a endpoint the is the oral and The to administration formulation mild-to-moderate looked placebo. study placebo XXX secondary overall were a enteric capsule randomized for X:X with XX XX trial active in endpoints. tolerated cohort days. trial Phase of difference using receive to X, enrolled milligrams Slide patients Ib with

endpoints Slide of into we the cytokine lesion data endpoints today. from these production. reporting the provides from The and are severity clinical are biomarkers the score, endpoints and These secondary that skin immunologic we EDPXXXX. described insights potential cell benefit biopsies On effects blood X, of cellular biomarkers

Now would Slide background I lesion X, on severity you give like moving the to to more score.

sensitive severity the lesion. period score, severity severity system score lesion clinical and disease body in only disease across when The a and measures with measure lesions we study The of measure individual severity in for same score scale PASI score sensitive measures same changes captures PASI thickness period. dosing of underlying same on is the the redness, single scaling element the the changes with days, surface As of lesions this severity XX-point changes component mild-to-moderate PASI the is the the lesion all as psoriasis. dosed lesion a patients is for for XX the score tracking it score a lesion a and period. that which focused lesion lesion change short scoring measures. for uses the severity underlying is across combines The psoriatic dosing a on area

a shows pleased X mean Change red in score compared in scores denoted points clinical severity I line for placebo were signal reduction dosed observed in significant cohort. severity black the severity who treated patients this patient am to EDPXXXX show lesion the early mean lesion evidence lesion of with line. of and X a shows to you Slide first patients is of in X.XX the by a with of statistically score increase by EDPXXXX. points denoted

period, across increasing in improvement reached be in of over trend anti-inflammatory agents mild-to-moderate plateau dosing over generally with a would we not X This The downward response. which effects line evaluated category benefit indicates even with psoriasis X a observed for improved the see II. the of as the effect that longer in have period dosing can or Phase will be months. EDPXXXX You

is The individual the this the slide reduction X The the to changes short-duration with XX lesion patients shows effect severity from over in XX, for X it’s in period. XX% in the of at received ranges group So severity score that cohort. low-dose this day in move marked each of EDPXXXX notable the and XX to days the reductions Slide having given cohort magnitude lesion score. subjects

the we’ve clinical division measured have basal Psoriasis here on received skin mitotic XX, Now in in could count. X.XX described basal red, skin shown EDPXXXX, in for we cellular biopsy. EDPXXXX of biopsies. biomarker the reduction compared the consistency we is increased data be is what a signal-finding per and epithelial we on of seen. shows in effect looking no reductions basal consistent mean mitotic in The measured reduction exactly skin, biomarkers the with cells driven in lesion mitotic of and cellular in the this, cells shown across is the the This a in squared millimeter severity count counting are patients Patients change epithelial by layer receiving Slide In to black. epithelial scores. by biomarkers cell pathology who the and in placebo this achieved like shown endpoints, of who a seen data are trial this scores

cell These baseline was biomarkers, they the biomarker a non-specific XX, to we level at analysis when move blood stimulated peripheral the induction look data. data of the of last The So peripheral cells are dosing at we Slide which period. can the immune at the blood an of of to the now with measured stimulant. is cell are LPS, immune of by produced level induction end and immune cytokines

graph down-regulated EDPXXXX ratio at to most the of data informative the compared no of as the for the XX shows these at day end the for X. in way period these reduction with cytokines The cytokines look the day placebo dosing compared red group. is in reductions up-regulated cytokines So, to shown at to

data of immune initial these evidence So EDPXXXX modulate that the can provide cells. systemic behavior

a I’d was of lesion today. So take to significant like well was on reduction range severity tolerated. XX, a lesion through Slide of score data XX%. summary to with presented specifically X% biomarker cells, just EDPXXXX a the II. of There were in you We anti-inflammatory reduction of stimulated to skin were systemic indicative consistent cytokine changes a from immune now with scores. Phase into The EDPXXXX The cellular response reduction advance in plan severity response.

chosen current dose interim formulation We A The be will placebo-controlled psoriasis PASI with the three II B will The of selection. patients we formulation II XXX get goal score from clinical Phase weeks, to study our A. patients selection conducting at have the the A XX, against our XX XX trial and with mild-to-moderate formulation. study an two change Phase is and our Part in weeks. will in consist new enroll benefit, dose formulation data we plan in primary will The enteric be formulation capsule Part Slide On planning. arms, evaluating This in be approximately Part and The of optimal will analysis testing captured endpoint goal also placebo. for Part parts. from at

We different enroll Part in subjects optimal testing of XXX plan to three B doses approximately arms, against four formulation in placebo. our

of selection to to We a our expansion made clinical core inflammatory the psoriasis study. of Phase EDPXXXX into decision portfolio starting the trials conclusion addition remains we following the program, planned once A psoriasis these have anticipate In other in formulation strategy. diseases Part of trials II

rheumatoid EDPXXXX indication and psoriatic about arthritis, think such we investigate spondylarthritis, diseases opportunity to active we dermatitis in the have as As asthma. expansion, arthritis, atopic

biologic with that patients from a benefit profile of could of oral millions are there potential together, novel potentially a Taken EDPXXXX.

the XX is presented of reminder a new previously. formulation Slide that Evelo data

commercial in see enable As signal in EDPXXXX compared pill shows enteric may optimize in new the the both to burden. of blue the response new right-hand increase in to the formulation presentation on formulations from increase the potency of the clinical XX-fold dose X to reducing side formulation models, green. an This the up you and can preclinical us the formulation

in clinical trial we was signals capture the from to to to the moving interim with and EDPXXXX of pharmacodynamic The of data a and tolerability and Phase effect. endpoint similar XX reported Now EDPXXXX trial secondary early of Phase of Ib the psoriasis. Ib primary safety endpoint today Slide trial ongoing design

psoriasis XX XX patients XXX dosed EDPXXXX reporting grams. in with data are mild-to-moderate of We dosed with from patients and X.X milligrams

a did clinical any with Slide dose. at from overall XXXX in biomarkers. the EDPXXXX EDPXXXX, which high patients we measures placebo. EDP in reduction X.X-gram indicates in well no to cell tolerated skin cell changes XX, response pharmacodynamic EDPXXXX, showed blood difference see was not or Moving Unlike as cytokines, with a

Slide XX The high EDPXXXX. biomarkers on way same biomarkers in cell at response the previously are shown those indicative the illustrates as are immune pharmacodynamic of for effect a presented the dose. peripheral

the cytokine As arm. dosing no you a reduction and period with in at production end compared milligram X.X-gram group the can for see, the dose, reduction at the graph the placebo of shows the XXX

cohort a Phase patients. of mild-to-moderate we’re potential these effects XX, current data exploring the on formulation the Moving focusing the given to Slide EDPXXXX in dermatitis of atopic Ib new trial

We expect this to report in cohort from early XXXX. data

EDPXXXX not data we psoriasis. have further in today, any we the Given shown will develop EDPXXXX

hand now over to I’ll Simba.

Simba Gill

Thank you, Duncan.

XX, turn clinical we revised So if we guidance. data Slide our to summarize

over late have XXXX. the data importantly, to the number of our XX We expected for next psoriasis EDPXXXX in months, data we’ve Phase in a added readouts IIa interim XX-week guidance and

we Moving in to we human platform are Slide opportunity support vision. data, these XX, that studies Phase II clinical first on advancing our today, evidence presented psoriasis. the Based from and into EDPXXXX

We other expect indications XX-week trial. inflammatory data expand of the after into interim that to

would like and may happy to vision. any team remarkable for you take have. to our We thanking our be conclude science our to their and would dedication at I by questions Evelo passion now

Operator

ahead. from I Instructions] go [Operator saw Morgan comes you. Matthew Harrison first Stanley. Please Thank question from our

Vikram Purohit

Hi, this is taking on Thanks our for Vikram Matthew. for question.

is commentary XXXX measure. on provided for I the So question our you data, LSS first guess, the some

wondering endpoints same were they scores. expectations data the see there year? PASI the there how We on then some formulation actual later if now you XXXX, for could there? a correlation is does Was are this if new in influence also And just there our direction? about then believe trended those could to question secondary wanted the We generated your if that on the is commentary you data And there provide you how on pointed coming commentary far any in you at provide looked impact any other is I study. so

Simba Gill

Thanks is I questions. XXXX. this as Simba. Vikram, Hi, on Duncan as answer both for the am going to your questions let XXXX well

Duncan McHale

questions. the for Thanks

today. the at the are And but scores time. it’s sensitive Yes, same we short that’s of demonstrate we that we a said we throughout presentation and PASI move in that we we’ve XX got ones With as but pharmacodynamic endpoints. is robust all the is this process actually regard study. we in reason trending measure. sort And what there actual a pharmacodynamic other other The we a that will for the – are really a report, the will see placebo, the Phase actual of as this the be reduction way. pleased clinical endpoints looking lesional the we looking period over other we’ve pharmacodynamic the a the we of of it’s dose are the today XX, compared same used severity that the tool We II be time study very period presented demonstrated still analysis lesion the to – PASI through the This response. In there in more that in days is score, with is have ones did a something biomarkers reported score mild-to-moderate So the were score are over signal-finding and that’s PASI is at. examining are pharmacodynamic the response of lowest the group said trends. we treated measure during short suited our as in is not obviously, you a such group a to

So once have conference of scientific we was? others will of part what the a those. the second question presented analysis forgot the I future the at be finished

Vikram Purohit

part of XXXX the formulation second question. was the

Duncan McHale

increase Yes. test a gives microbes the strategy XXXX translating it changes seen for pharmacodynamic they us it’s The and the we different actually is also what encouraging XX-fold in multiple not biomarker tested. portfolio to seen in data the have XXXX, same very cell We’ve but data multiple into The may immune dose the different respond new as response. for the not always indications. clinical at because And to was indications potency. formulation a mainly

actually potency formulation the benefit. potential gain valuable in feel information still to we piece testing very So dermatitis atopic of higher is and a

Vikram Purohit

you. Thank understood. Okay,

Duncan McHale

Thanks.

Operator

Chris from you, Thank Cowen. comes from ahead. question our Shibutani go next Please

Chris Shibutani

Phase patients I sharing give also further what be interim an be you You that with you Can about point? that Will the will triggering at a you. mentioned that your blend studies in sense II mild moderate thank might autoimmune you guess, additional point. will be Or us the of discussed for Great, information the look, versus decision at taking be XX-week study? us?

Simba Gill

Hi, Chris.

So question. me let the take second

yes, we late potential sharing we indications. interim will will guidance And formal expect to XXXX. data, we’re release at giving that guidance So on that additional expansion XX-week we and time, be the in actually giving into that be

as for understand, Chris, potential significantly Importantly, EDPXXXX goes you psoriasis. the beyond

expanding positive range subject So to a into continued we’ll again, in of data, that And inflammatory we would anticipate indications. guidance late the potentially additional XXXX. on give half of second

part question, the answer the that. I’ll first let of On Duncan

Duncan McHale

Simba. Thanks,

terms equal care study, sort that. a And in body the a with of study. Phase so mild enrolled area subjects surface so first-in-human X% to this to end less It Ib subjects on the were in are than or for of was of they psoriasis, these of

have an a we into, mild that in provide to II in move will population. EDPXXXX but more disease evidence some disease we October that mild no the more advisory the There’s actually will key moving opinion leaders only into moderate well may or well. For to look meeting into should work and and advice, study are – Phase moderate as we with

population. patient going in moderate we’re will so population clearly we broaden II it’s take underserved in that So the Phase to but advice

Chris Shibutani

the the very of formulation modality work provide talking has in that rigorous Got potency. grams, be little And about to hoping as are it. administering? if are the of little are terms not, in the is Can increasing us you XXXX? And XXx how the of it potency enable to of obviously distinctions understand fashion, is would that as be it able on what think increasing you’re I formulation a can potency. heft just Xx then dosing that Just you And you clarity what a that you’re formulation? help ultimate differences well doing work about the this in apply going there in that which be to just there is you to would at novel talking you’re with merely clarity kind in that I’m that whereas would going a dose, may with a XXXX terms And the X.XX instance, helpful. XXXX for that there, you therapeutic difference, looking metric a just is actually is

Simba Gill

Yes. Chris, Officer, will Scientific that question. let I Mark, our Chief answer

Mark Bodmer

the the we’ve maximize micro of engage thrust doing the been the of the studies to with ability gut. in to formulation target Chris, the cells is

to drug So as small this then in we quickly the and conditions new had the as for against of specification intestine, into the possible and release stomach, formulation to the what protect that’s course, a passes does. as

same. what’s substance it’s drug models in exactly that and and doing of potency difference the the in forward. is So that’s is measure changing exposure to this rate preclinical leading What taking we’re the it’s we the

same the the the the exactly to EDPXXXX and effect the think microbes which the biology we of cells, EDPXXXX, the distribution intestine. the and seeing in of upper target particularly part appropriate related with We’re is interaction of the for for of small gut

target So X formulation change It’s of the here. and and appropriate this lumen release for stage notion based of the the to small there’s getting both engagement it’s the part microbe. intestine timing on cell within of of maximal same

Simba Gill

formulation. the today Phase that taking of importantly, something very very lowest said as as to just with Chris, the at, we’ve dose both that’s with things And EDPXXXX the new on the data forward looked reported call, obviously, original is the repeat And with the the formulation. that’s one we in the we II are original well encouraging it’s

in looking up is the asked that something new is be you going in a the of to terms X dose formulation, which more X dosing, questions to investigating we’re at XX-fold II at the potent. and both on and Phase So potency

So point it’s components changes duration drive Duncan to in important clinical emphasize. this the days Again, it extended but drive systemic mentioned are to on immunology XX on short to also call, therapy. and response. is other the duration very of an changes the in a

doses that extended in at again a therapy. II low with to new that very formulation we’ve be seen encouraging summarized. in So also the Phase we short an period higher of effects addition looking The duration the the will dose and

Chris Shibutani

much Thank it. comments. you very Got the for additional

Simba Gill

Thank you, Chris.

Operator

Thank you.

go BMO Our Matthew next Luchini ahead. comes Please from question Capital. from

Matthew Luchini

the congrats Hi, thanks. morning on Good and progress.

So, a couple for me.

a And I could based some bit baseline about Maybe measures I perhaps drove provide bit was on you any a other some of specific if at the patient you the talk you us could the little patients? finally, muted in it, a results? data, how responses. patient guess, tell as clarification on back of breakdown then Slide moderate just you And able characteristics then and talk mild was LSS if And or the in that could have color you of range look little the patients we single in the response substantial today’s maybe just case a selected? First, patients lesion. wondering what and you a given else, I to be lesion patient versus XX think seen might response point in more each secondarily, the something missed of do

Simba Gill

the congratulation. for thanks And Thanks.

So answer questions. Medical brilliant all I again right Officer think, our the those person is Chief to

Duncan McHale

Sure. Simba. Thanks,

have for is EDPXXXX, we investigator something all lesion, the of What investigator obviously trained same appropriately the we this the at the actually did scoring. of that is by choice the of terms In who done so the did site.

has most we so, lesion, sort around lesion. a so are the the chose of that highest score scores the for XX They lesion generally of X score points. to they large chose can the And which sort of lesional

the fast hard but no the So the chose or a lesion and is chose lesion so he that we investigator and the in can she that score reduction lesion see with chose there rules, high a score.

lesional So the choice lesion. of the score, that’s

you lesional so rate as It’s certainly mild the the on heal. and range you we the responding score the psoriasis that no that anti-inflammatory if in across that’s weeks need a why The response. in benefit response. terms we the of at allowing of out had of variability treat baseline, more able in to responses fact severe. XX you’re really agents sort really XX treating look of population. Phase altered depth II longer there’s the as full are evidence to the patients And that’s study at clinical to category a range to quite actually there’s the is in healing that all response the If not you the you responses, of class expect. skin is function responses or inflammation and the period the variability bit original of sort you’re the psoriasis, And And to the score to entirely of to have look population. the baseline measure might the why that a of responses took really what be the doing understand We duration actually will across treating a with more

XX. skin So markedly. think here variability just scores in so was mild we the the times had final the moderate mild we just scores maybe That’s lesion do that this question often know of slightly because is healing out just sort first-in-human quite mild population. probably and vary all of these were was range. although study, to X, here into The seeing you’re were what of The there X, the patients disease individual that is I take and

scores in the classed of So mild, but disease to as range. be lesion XX-type were overall, X the the actually sort will

Matthew Luchin

Great. for additional the Thank you color.

Operator

you. Thank

from Please question comes go Jefferies. next ahead. Our Chris from Howerton

Chris Howerton

the seen so seen were on little in events more were a terms group. I were Congrats the quite for could set. wondering them were in question But were as frequent they profiles same the taking I’m you far, data. most the think what the of information if that placebo safety of this but comments that of Great. what within provide adverse data few a I the terms asked already think, my Thanks we’ve

Simba Gill

Duncan? sure. Chris,

Duncan McHale

been that really tolerated, seen serious taking of little of the to. the no headaches severe – analgesia majority abdominal medicines. nothing a adverse bit profiles well And with moderate mild events the were the bloating few that seen of intensity. has adverse The EDPXXXX This no adverse in Happy acetaminophen-type events, we’ve events we’ve The events incredibly X had, only Sure, event Chris. that were treated with and again, X pain. was anybody a events. or standard stopped we’ve couple

And these we in studies. always something that sorts see of

So that only it really EDPXXXX AEs in reported. the was – were were those X the cohort

Chris Howerton

it. Got

I then information think potent. And the same formulation I be that the there information on was and XXXX great shown Okay. understanding that for formulation new forward. more moving XXx disclosed is I’m for work XXXX. for my been was has that doing that, And you’ve not to But formulation sure guess,

I formulation of And operational new be just confirm that a kind be was trying would would what not, what required maybe So status the move asset. to steps that to of if forward? of

Simba Gill

do to want take that? Mark, you

Mark Bodmer

Yes.

EDPXXXX. with or Status greater EDPXXXX. So was ready that the data that possibly which manufactured in EDPXXXX. we’re and for EDPXXXX for the done for happens the original actually EDPXXXX in of pursuing the improvement same study, actually a put Duncan the effect EDPXXXX. atopic be we’ve same, material for we public GMP for the dermatitis, formulations and XX XX- is have range to formulated XX-fold the the work – even mentioned The to But of new domain were

Chris Howerton

it. Got

features? of of terms with be so can those moving the forward any number And you is seen we’ve of there frequency effect, kind and Okay, far your what for of additional information to dosing in to and great. respect terms the maybe provide And potential us the food pills in data? then in just might what expectations maybe

Simba Gill

say new end Yes. with us think the able data the which already Chris, as e.g., those attractive forward we presented commercial be or pill per thing can ideally formulation, things move an day formulation, give is, up that I will one two the obviously today, we’ve to between equivalent. we one is confidence we

discussing So this that’s as stage. much as at we’re

Chris Howerton

I ask and was more formulation of of formulation. current novel if new formulation, words just then one you a maybe a features called of And that the Okay. question could then interesting terms That’s enteric the that great. one in I the formulation the found

of curious the of just meant terms in was I between two. terms differentiation and what the specifically, So in word that it’s choice

Simba Gill

ahead. Mark, go

Mark Bodmer

Yes.

specifically So both new which a standard we these of original they disclosed actually enteric the put. The the protect enteric at what a pharmacology sense The deleterious to haven’t the formulation lyophilized acid, formulation stomach is an with into in the Duncan which on referred enteric is. is from effect are microbes. presentation. is the capsule formulation the that They coat is weights alternative material new of

formulation we some facets of and which when commented it’s the about we this think enterically exposure. exposure at but I are speed talked what of We’ll it. increases additional we They accessible the release. some new technology, the rate point first which there this, but a haven’t is revealed commercializable discuss both are but coated,

Chris Howerton

well again much very Got Alright positive data. it, on you congratulations okay. the and thank

Simba Gill

Thanks, Chris.

Operator

Our Thank Please from go question you. [Operator next Taylor comes Chardan. Feeley ahead. Instructions] from

Taylor Feeley

been about answered. morning. score. question with one start my this I’ll taking lesion But have for Many I thanks guess, Hi, severity the of them

the you patient reduction, psoriasis you then could ratio on And just of can other it look X-point much. of a that the maybe cytokines? just the is down. or you I cytokine change clarify Thank that number ratio the cytokines I the similar help those just that are if severity assay? currently maybe to therapeutics and up what may us For it’s population lesion used and a went But exist in fully that metric. so make timescale on You sure versus like? want against went fold that score understand cytokines this the mentioned benchmark in help data this that understand

Simba Gill

need the unmet what Good patient We morning. we’re take benchmark which Taylor, first is segment which are EDPXXXX non-applicable. for question. there addressing let with into so therapies is the existing can’t me because

therapies clinical until other with not measure the after there said, because as sensitive the LSS, response of mild-to-moderate populations in do historical actually most is mild-to-moderate patients So good go disease. it isn’t We’ve Duncan used benchmarking.

question. that cytokine do to handle you answer that’s Duncan, So want the the question? to

Duncan McHale

of number following non-immune what group you following with short that it Yes. number by we the cells was stimulant. cytokines. down-regulated as the of saw fold in we I down-regulated the It was that compared stimulation or actual the mean saw of immune And the after changed. more to of wasn’t baseline the were question that is cytokine cytokines cytokines stimulation was up-regulated days treated numbers. sort answer the But the LPS treatment see it XX of

Taylor Feeley

magnitude able that? on discuss of great. be color to Okay, to Any or too change early is it

Duncan McHale

it’s probably early and as I’m a intra-individual lot there’s too in of, sorts I aware well variability, you that small and of of sure number. you’re to find what is mean do assays these

Operator

last Please go Chris comes Shibutani Cowen. from Our question ahead. from

Chris Shibutani

for on very XX thank Then we XX and there. we’re follow-ups. compare results at frame how I endpoint should Great, the looking that so and believe, benchmarks, you’ll weeks? is the PASI the II you provide if the much for taking program Phase

to I from that quickie. last described for or patients, familiar some results benchmarks we’re not interpreting us mild-to-moderate we’ll you’ve refer necessarily of references Phase tested. with can the But you the the have As there, appropriate a for II? have present have one And that then you been so very lot therapeutics that context

Simba Gill

So, couple of points.

on II. we’ll guidance Chris, into the early And us Phase key that for on right PASI full much comparators in you probably the too get will now. think, as forward, go detail appropriate more too yes, So to readout I be we give

Chris Shibutani

control changed that just your you IST. in no that. terms XXXX, the that communication longer noticed say on be study that related as then communicated? will terms Has the Okay, lastly, of the great. as in I how be this well anything will timing you to guidance on in of providing of results be involvement, keen We’ll for And

Simba Gill

just have No. control. that decided We Nothing’s Chris. had changed there, operational we – never

So made to which giving we changed. on nothing’s because can’t speed occurring, but the stop we at it’s decision impact a guidance that formal

Operator

session. This to call Gill concludes time, I’d remarks. like turn closing for back our Simba to the this Q&A At

Simba Gill

us. the So for Evelo. said, you as thank continued obviously, interest very Appreciate I important an everybody. day in much It’s,

patients. human signals continuing together We We’re we for the you. and forward that, really appreciate delighted first positive with build look Thank data support And supporting biomarker the Evelo to to report and questions. data in to showing the clinical you. have time,

Operator

Thank you, program. the attending gentlemen, This today’s conference. and for ladies concludes

disconnect. all day. may You Good

Evelo Biosciences (EVLO) 12 Aug 192019 Q2 Earnings call transcript